Based on this knowledge, different Eg5 inhibitors were tested on BC as a new possible therapeutic strategy [19,20] finding a correlation between Eg5 activity and ER+/PR+ BC occurrence, thus indicating Eg5 inhibitor therapy as a promising strategy to treat patients with ER+/PR+ BC rather than hormonal therapies [21,22]. The gene discussed is PGR; the disease is breast cancer.